UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
Date of Report: June 28, 2022
Commission File Number: 001-36891
Cellectis S.A.
(Exact Name of registrant as specified in its charter)
8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
General Meeting
Cellectis S.A. (the “Company”) held its Combined Ordinary and Extraordinary General Meeting (the “Meeting”) on June 28, 2022. Filed as Exhibits 99.1 and 99.2 hereto are the press release and the voting results for the Meeting, respectively.
EXHIBIT INDEX
| Exhibit |
Title | |
| 99.1 | Press Release, dated June 28, 2022. | |
| 99.2 | Voting Results for the Combined Ordinary and Extraordinary General Meeting. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CELLECTIS S.A. | ||||||
| (Registrant) | ||||||
| June 28, 2022 | By: | /s/ André Choulika | ||||
| André Choulika | ||||||
| Chief Executive Officer | ||||||
Exhibit 99.1
PRESS RELEASE
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting
Held on June 28, 2022
New York (N.Y.) - June 28, 2022 - Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 28, 2022 at its head office in Paris, France.
At the meeting, during which 67.23% of voting rights were exercised, Resolutions 1 through 23 and 25 were adopted. Resolutions 24 and 26 were rejected.
The detailed results of the vote and the resolutions are available on the company’s website:
https://www.cellectis.com/en/investors/general-meetings/
About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases.
Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).
For more information, visit www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.
For further information, please contact:
Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com
Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300
Investor Relation contact:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 (617) 430 7577
Exhibit 99.2
CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 28, 2022
VOTE RESULTS
Ordinary Resolutions
| Nb | Resolution | Result | For | Against | Vote withhold | Total votes | Shares represented by the votes cast |
Percentage of the share capital the votes cast
|
Out of vote voting rights |
Null voting |
Quorum | |||||||||||||||||
| Votes | % | Votes | % | Votes | % | |||||||||||||||||||||||
|
1 |
Approval of the annual financial statements for the financial year ended December 31, 2021 | |||||||||||||||||||||||||||
|
1 |
Carried |
35 525 535 |
99,91% |
31 864 |
0,09% |
76 147 |
- |
35 557 399 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
2 |
Approval of the consolidated financial statements for the financial year ended December 31, 2021 | |||||||||||||||||||||||||||
|
2 |
Carried |
35 511 370 |
99,91% |
32 029 |
0,09% |
90 147 |
- |
35 543 399 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
3 |
Appropriation of results for the financial year ended December 31, 2021 | |||||||||||||||||||||||||||
|
3 |
Carried |
35 519 285 |
99,90% |
36 994 |
0,10% |
77 267 |
- |
35 556 279 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
4 |
Allocation of losses carried forward to the “share premium” account | |||||||||||||||||||||||||||
|
4 |
Carried |
35 519 402 |
99,89% |
37 477 |
0,11% |
76 667 |
- |
35 556 879 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
5 |
Determination of the total remuneration of the non-executive members of the Board of Directors | |||||||||||||||||||||||||||
|
5 |
Carried |
31 764 600 |
89,18% |
3 852 491 |
10,82% |
16 455 |
- |
35 617 091 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
6 |
Ratification of the appointment of an Observer decided by the Board of Directors | |||||||||||||||||||||||||||
|
6 |
Carried |
35 261 439 |
99,17% |
295 772 |
0,83% |
76 335 |
- |
35 557 211 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
1/5
CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 28, 2022
VOTE RESULTS
Ordinary Resolutions
| Nb | Resolution | Result | For | Against | Vote withhold | Total votes | Shares represented by the votes cast |
Percentage of the share capital the votes cast
|
Out of vote voting rights |
Null voting |
Quorum | |||||||||||||||||
| Votes | % | Votes | % | Votes | % | |||||||||||||||||||||||
|
7 |
Appointment of a new director (Mr. Donald A. Bergstrom) | |||||||||||||||||||||||||||
|
7 |
Carried |
35 057 038 |
98,59% |
500 363 |
1,41% |
76 145 |
- |
35 557 401 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
8 |
Appointment of a new Director Mr. Axel-Sven Malkomes | |||||||||||||||||||||||||||
|
8 |
Carried |
35 082 096 |
98,66% |
474 695 |
1,34% |
76 755 |
- |
35 556 791 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
9 |
Authorization to the Board of Directors to buy back shares of the Company | |||||||||||||||||||||||||||
|
9 |
Carried |
35 063 860 |
98,63% |
487 983 |
1,37% |
81 703 |
- |
35 551 843 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
2/5
CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 28, 2022
VOTE RESULTS
Extraordinary Resolutions
| Nb | Resolution | Result | For | Against | Vote withhold | Total votes | Shares represented by the votes cast |
Percentage of the share capital the votes cast
|
Out of vote voting rights |
Null voting |
Quorum | |||||||||||||||||
| Votes | % | Votes | % | Votes | % | |||||||||||||||||||||||
|
10 |
Authorization to be granted to the Board of Directors to reduce the share capital by cancelling shares under the authorization to buy back its own shares | |||||||||||||||||||||||||||
|
10 |
Carried |
35 515 847 |
99,88% |
41 528 |
0,12% |
76 171 |
- |
35 557 375 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
11 |
Delegation of authority to be granted to the Board of Directors to increase the capital by issuing ordinary shares or any other securities with cancellation of shareholders’ preferential subscription rights in favor of a category of persons meeting specified characteristics (investors with experience in the health or biotech sector) | |||||||||||||||||||||||||||
|
11 |
Carried |
34 658 582 |
97,47% |
899 079 |
899 079 |
75 885 |
- |
35 557 661 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
12 |
Delegation of authority to be granted to the Board of Directors to increase the capital by issuing ordinary shares or any other securities with cancellation of shareholders’ preferential subscription rights in favor of a category of persons meeting specified characteristics (e.g. credit institution, investment services provider or member of an investment pool guaranteeing the completion of the issue in question), including, as the case may be, within the framework of an equity financing program known as “At-the-market” or “ATM”. | |||||||||||||||||||||||||||
|
12 |
Carried |
34 652 483 |
97,46% |
903 976 |
2,54% |
77 087 |
- |
35 556 459 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
13 |
Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares or any other securities, with cancellation of shareholders’ preferential subscription rights in favor of a category of persons meeting specified characteristics (industrial companies, institutions or entities active in the health or biotechnology sector) | |||||||||||||||||||||||||||
|
13 |
Carried |
34 657 564 |
97,47% |
899 097 |
2,53% |
76 885 |
- |
35 556 661 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
14 |
Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares or any other securities with cancellation of shareholders’ preferential subscription rights in favor of a category of persons meeting specified characteristics in the framework of an equity or bond financing agreement | |||||||||||||||||||||||||||
|
14 |
Carried |
34 654 845 |
97,46% |
901 651 |
2,54% |
77 050 |
- |
35 556 496 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
15 |
Delegation of authority to be granted to the Board of Directors to decide on the issuance of ordinary shares to be issued immediately or in the future by the Company, with cancellation of the shareholders’ preferential subscription rights, to the benefit of a category of persons meeting specified characteristics within the framework of an equity financing program on the American Market known as “At-the-market” or “ATM”. | |||||||||||||||||||||||||||
|
15 |
Carried |
34 656 035 |
97,47% |
900 609 |
2,53% |
76 902 |
- |
35 556 644 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
3/5
CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 28, 2022
VOTE RESULTS
Extraordinary Resolutions
| Nb | Resolution | Result | For | Against | Vote withhold | Total votes | Shares represented by the votes cast |
Percentage of the share capital the votes cast
|
Out of vote voting rights |
Null voting |
Quorum | |||||||||||||||||
| Votes | % | Votes | % | Votes | % | |||||||||||||||||||||||
|
16 |
Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares and/or any other securities, with the shareholders’ preferential subscription rights maintained, | |||||||||||||||||||||||||||
|
16 |
Carried |
35 063 590 |
98,61% |
493 056 |
1,39% |
76 900 |
-
|
35 556 646 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
17 |
Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares and/or any other securities, with cancellation of shareholders’ pre-emptive subscription rights, by way of a public offering (other than the offerings referred to in paragraph 1 of Article L. 411-2 of the French Monetary and Financial Code) | |||||||||||||||||||||||||||
|
17 |
Carried |
34 650 068 |
97,45% |
906 126 |
2,55% |
77 352 |
- |
35 556 194 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
18 |
Delegation of authority to be granted to the Board of Directors to increase the share capital by issuing ordinary shares and/or any other securities, with cancellation of the shareholders’ preferential subscription rights in the context of an offer referred to in paragraph 1° in of Article L. 411-2 of the French Monetary and Financial Code | |||||||||||||||||||||||||||
|
18 |
Carried |
34 650 995 |
97,45% |
905 651 |
2,55% |
76 900 |
- |
35 556 646 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
19 |
Delegation to the Board to increase the number of shares to be issued in the event of a capital increase with or without preferential subscription rights | |||||||||||||||||||||||||||
|
19 |
Carried |
34 644 486 |
97,48% |
897 381 |
2,52% |
91 679 |
- |
35 541 867 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
20 |
Overall limitations on the amount of issues made under the Eleventh resolution to Nineteenth resolutions | |||||||||||||||||||||||||||
|
20 |
Carried |
35 276 317 |
99,21% |
280 058 |
0,79% |
77 171 |
- |
35 556 375 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
21 |
Delegation of authority granted to the Board of Directors to increase the capital by incorporation of premiums, reserves, profits or other | |||||||||||||||||||||||||||
|
21 |
Carried |
35 060 503 |
98,61% |
495 362 |
1,39% |
77 681 |
- |
35 555 865 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
4/5
CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 28, 2022
VOTE RESULTS
Extraordinary Resolutions
| Nb | Resolution | Result | For | Against | Vote withhold | Total votes | Shares represented by the votes cast |
Percentage of the share capital the votes cast
|
Out of vote voting rights |
Null voting |
Quorum | |||||||||||||||||
| Votes | % | Votes | % | Votes | % | |||||||||||||||||||||||
|
22 |
Authorization to the Board of Directors to grant options to subscribe for or purchase shares of the Company | |||||||||||||||||||||||||||
|
22 |
Carried |
34 373 630 |
96,51% |
1 242 715 |
3,49% |
17 201 |
- |
35 616 345 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
23 |
Authorization to the Board of Directors to proceed with the free allocation of existing and/or new ordinary shares | |||||||||||||||||||||||||||
|
23 |
Carried |
34 811 605 |
97,74% |
804 364 |
2,26% |
17 577 |
- |
35 615 969 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
24 |
Delegation of authority to be granted to the Board of Directors to allocate share subscription warrants giving the right to subscribe to ordinary shares of the Company - suppression of the preferential subscription right in favor of a category of persons meeting specific characteristics | |||||||||||||||||||||||||||
|
24 |
Rejected |
16 002 881 |
60,12% |
10 617 406 |
39,88% |
9 013 259 |
- |
26 620 287 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
25 |
Overall limits on the amount of issues made under the above issues made under the Twenty-second resolution and the Twenty-third resolution above | |||||||||||||||||||||||||||
|
25 |
Carried |
35 486 528 |
99,84% |
55 867 |
0,16% |
91 151 |
- |
35 542 395 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
|
26 |
Delegation to the Board of Directors to proceed with an increase in the share capital, the subscription of which would be reserved for the members of a company savings plan established pursuant to Articles L. 3332-1 et seq. of the Labor Code | |||||||||||||||||||||||||||
|
26 |
Rejected |
6 610 718 |
18,57% |
28 994 859 |
81,43% |
27 969 |
- |
35 605 577 |
30 600 674 |
67,238% |
0 |
0 |
67,238% | |||||||||||||||
5/5